Psychiatr. praxi. 2020;21(1):40-46 | DOI: 10.36290/psy.2020.010
Aripiprazole in the form of long-acting intramuscular injections in the clinical practice
- Psychiatrická klinika LF UK a FN Hradec Králové
- Neurologická LF UK a FN Hradec Králové
Aripiprazole in the form of long-acting intramuscular injections (ALAI) is intended for maintenance treatment of schizophrenia in adult patients stabilized on oral aripiprazole. The recommended maintenance dose is 400 mg administered once a month. It is the first long-acting antipsychotic drug with partial agonistic action on D2 receptors. Two large registration trials have confirmed the efficacy of ALAI in maintenance treatment of schizophrenia. ALAI was more effective than placebo and displayed non inferiority to oral aripiprazole in delaying psychosis exacerbation or impending relapse and in reducing relapse rates. ALAI is well tolerated, with its adverse effect profile corresponding to that of the tablet formulation. In an indirect comparison with other second-generation long-acting injectable antipsychotics, the use of ALAI poses a lower risk of weight gain, metabolic symptoms, hyperprolactinaemia, and sedation. ALAI is easy to use, with practical guidance on how to switch from other antipsychotics being available.
Keywords: aripiprazole, long-acting injection, tolerance.
Published: May 15, 2020 Show citation
References
- Aitchison KJ, Bienroth M, Cookson J, Gray R, Haddad PM, Moore B, Ratna L, Sullivan G, Taylor D, Taylor M, Goodwin GM. A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol 2009; 23: 231-240.
Go to original source... 
Go to PubMed... - Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389. Go to original source... Go to PubMed...
- Fagiolini A. Practical guidance for prescribing with aripiprazole in bipolar disorder. Curr Med Res Opin 2008; 24: 2691-2702. Go to original source...
- Fagiolini A, Brugnoli R, Di Sciascio G, De Filippis S, Maina G. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother 2015; 16: 727-737. Go to original source... Go to PubMed...
- Fagiolini A, Alfonsi E, Amodeo G, Cenci M, Di Lella M, Farinella F, Ferraiuolo F, Fraguas D, Loparco N, Gutierrez-Rojas L, Mignone ML, Pataracchia G, Pillai G, Russo F, Sanchez-Gistau V, Spinogatti F, Toscano M, Villari V, De Filippis S. Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opin Drug Saf 2016; 15: 449-455. Go to original source...
- Fleischhacker WW, Sanchez R, Johnson B, Jin N, Forbes RA, McQuade R, Baker RA, Carson W, Kane JM. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013; 28: 171-176. Go to original source... Go to PubMed...
- Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Baker RA, Forbes RA, McQuade RD, Carson WH, Fleischhacker WW. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73: 617-624. Go to original source... Go to PubMed...
- Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013; 150: 281-288. Go to original source...
- Masopust J, Mohr P, Anders M, Kopeček M. Aripiprazol ve formě dlouhodobě působících intramuskulárních injekcí. Psychiatrie 2014; 18: 90-97.
- Masopust J. Aripiprazol v léčbě schizofrenie a bipolární poruchy. Praha: Mladá fronta - Medical services 2019; 135.
- Mohr P, Kopeček M, Brunovský M, Páleníček T. Klinická psychofarmakologie. Praha: Maxdorf 2018; 568.
- Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander AG, Hertel P, Andersen HS, Eramo A, Loze JY, Potkin SG. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 2015; 168: 498-504. Go to original source...
- Raoufinia A, Baker RA, Eramo A, Nylander AG, Landsberg W, Kostic D, Larsen F. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin 2015; 31: 583-592. Go to original source...
- Stahl SM. Stahl's essential psychpharmacology. Neuroscientific basis and practical applications. 4th ed. Cambridge: Cambridge Universtiy Press, 2013.
- Švestka J. Aripiprazol - antipsychotikum nové generace s jen parciální agonizací dopaminových D2/D3 a serotoninových 5-HT1A receptorů. Psychiatrie 2003; 7: 279-289.
- Švestka J, Höschl C, Anders M, Janů L, Masopust J, Mohr P, Přikryl R. Možnosti použití aripiprazolu v léčbě bipolární afektivní poruchy. Konsensus expertů v České republice. Psychiatrie 2010; 14: 218-224.
- Švestka J, Látalová K, Masopust J, Přikryl R, Mohr P. Aktuální poznatky o léčbě bipolární poruchy aripiprazolem: konsenzus expertů 2012. Psychiatrie 2012; 16: 111-119.
- Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. West Sussex, United Kingdom: John Wiley & Sons 2018; 854.